Qi Yong H Ai, Ho Sang Leung, Frankie K F Mo, Kaijing Mao, Lun M Wong, Yannis Yan Liang, Edwin P Hui, Brigette B Y Ma, Ann D King
{"title":"诱导化疗后弥散加权成像的变化优于RECIST指南对晚期鼻咽癌远期预后的预测。","authors":"Qi Yong H Ai, Ho Sang Leung, Frankie K F Mo, Kaijing Mao, Lun M Wong, Yannis Yan Liang, Edwin P Hui, Brigette B Y Ma, Ann D King","doi":"10.1186/s40644-025-00854-4","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>To investigate change in diffusion weighted imaging (DWI) between pre-treatment (pre-) and after induction chemotherapy (post-IC) for long-term outcome prediction in advanced nasopharyngeal carcinoma (adNPC).</p><p><strong>Materials and methods: </strong>Mean apparent diffusion coefficients (ADCs) of two DWIs (ADC<sub>pre</sub> and ADC<sub>post-IC</sub>) and changes in ADC between two scans (ΔADC%) were calculated from 64 eligible patients with adNPC and correlated with disease free survival (DFS), locoregional recurrence free survival (LRRFS), distant metastases free survival (DMFS), and overall survival (OS) using Cox regression analysis. C-indexes of the independent parameters for outcome were compared with that of RECIST response groups. Survival rates between two patient groups were evaluated and compared.</p><p><strong>Results: </strong>Univariable analysis showed that high ΔADC% predicted good DFS, LRRFS, and DMFS p < 0.05), but did not predict OS (p = 0.40). Neither ADC<sub>pre</sub> nor ADC<sub>post-IC</sub> (p = 0.07 to 0.97) predicted outcome. Multivariate analysis showed that ΔADC% independently predicted DFS, LRRFS, and DMFS (p < 0.01 to 0.03). Compared with the RECIST groups, the ΔADC% groups (threshold of 34.2%) showed a higher c-index for 3-year (0.47 vs. 0.71, p < 0.01) and 5-year DFS (0.51 vs. 0.72, p < 0.01). Compared with patients with ΔADC%<34.2%, patients with ΔADC%≥34.2% had higher 3-year DFS, LRRFS and DMFS of 100%, 100% and 100%, respectively (p < 0.05).</p><p><strong>Conclusion: </strong>Results suggest that ΔADC% was an independent predictor for long-term outcome and was superior to RECIST guideline for outcome prediction in adNPC. A ΔADC% threshold of ≥ 34.2% may be valuable for selecting patients who respond to treatment for de-escalation of treatment or post-treatment surveillance.</p>","PeriodicalId":9548,"journal":{"name":"Cancer Imaging","volume":"25 1","pages":"32"},"PeriodicalIF":3.5000,"publicationDate":"2025-03-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11905565/pdf/","citationCount":"0","resultStr":"{\"title\":\"Change in diffusion weighted imaging after induction chemotherapy outperforms RECIST guideline for long-term outcome prediction in advanced nasopharyngeal carcinoma.\",\"authors\":\"Qi Yong H Ai, Ho Sang Leung, Frankie K F Mo, Kaijing Mao, Lun M Wong, Yannis Yan Liang, Edwin P Hui, Brigette B Y Ma, Ann D King\",\"doi\":\"10.1186/s40644-025-00854-4\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Purpose: </strong>To investigate change in diffusion weighted imaging (DWI) between pre-treatment (pre-) and after induction chemotherapy (post-IC) for long-term outcome prediction in advanced nasopharyngeal carcinoma (adNPC).</p><p><strong>Materials and methods: </strong>Mean apparent diffusion coefficients (ADCs) of two DWIs (ADC<sub>pre</sub> and ADC<sub>post-IC</sub>) and changes in ADC between two scans (ΔADC%) were calculated from 64 eligible patients with adNPC and correlated with disease free survival (DFS), locoregional recurrence free survival (LRRFS), distant metastases free survival (DMFS), and overall survival (OS) using Cox regression analysis. C-indexes of the independent parameters for outcome were compared with that of RECIST response groups. Survival rates between two patient groups were evaluated and compared.</p><p><strong>Results: </strong>Univariable analysis showed that high ΔADC% predicted good DFS, LRRFS, and DMFS p < 0.05), but did not predict OS (p = 0.40). Neither ADC<sub>pre</sub> nor ADC<sub>post-IC</sub> (p = 0.07 to 0.97) predicted outcome. Multivariate analysis showed that ΔADC% independently predicted DFS, LRRFS, and DMFS (p < 0.01 to 0.03). Compared with the RECIST groups, the ΔADC% groups (threshold of 34.2%) showed a higher c-index for 3-year (0.47 vs. 0.71, p < 0.01) and 5-year DFS (0.51 vs. 0.72, p < 0.01). Compared with patients with ΔADC%<34.2%, patients with ΔADC%≥34.2% had higher 3-year DFS, LRRFS and DMFS of 100%, 100% and 100%, respectively (p < 0.05).</p><p><strong>Conclusion: </strong>Results suggest that ΔADC% was an independent predictor for long-term outcome and was superior to RECIST guideline for outcome prediction in adNPC. A ΔADC% threshold of ≥ 34.2% may be valuable for selecting patients who respond to treatment for de-escalation of treatment or post-treatment surveillance.</p>\",\"PeriodicalId\":9548,\"journal\":{\"name\":\"Cancer Imaging\",\"volume\":\"25 1\",\"pages\":\"32\"},\"PeriodicalIF\":3.5000,\"publicationDate\":\"2025-03-12\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11905565/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Cancer Imaging\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1186/s40644-025-00854-4\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer Imaging","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s40644-025-00854-4","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
Change in diffusion weighted imaging after induction chemotherapy outperforms RECIST guideline for long-term outcome prediction in advanced nasopharyngeal carcinoma.
Purpose: To investigate change in diffusion weighted imaging (DWI) between pre-treatment (pre-) and after induction chemotherapy (post-IC) for long-term outcome prediction in advanced nasopharyngeal carcinoma (adNPC).
Materials and methods: Mean apparent diffusion coefficients (ADCs) of two DWIs (ADCpre and ADCpost-IC) and changes in ADC between two scans (ΔADC%) were calculated from 64 eligible patients with adNPC and correlated with disease free survival (DFS), locoregional recurrence free survival (LRRFS), distant metastases free survival (DMFS), and overall survival (OS) using Cox regression analysis. C-indexes of the independent parameters for outcome were compared with that of RECIST response groups. Survival rates between two patient groups were evaluated and compared.
Results: Univariable analysis showed that high ΔADC% predicted good DFS, LRRFS, and DMFS p < 0.05), but did not predict OS (p = 0.40). Neither ADCpre nor ADCpost-IC (p = 0.07 to 0.97) predicted outcome. Multivariate analysis showed that ΔADC% independently predicted DFS, LRRFS, and DMFS (p < 0.01 to 0.03). Compared with the RECIST groups, the ΔADC% groups (threshold of 34.2%) showed a higher c-index for 3-year (0.47 vs. 0.71, p < 0.01) and 5-year DFS (0.51 vs. 0.72, p < 0.01). Compared with patients with ΔADC%<34.2%, patients with ΔADC%≥34.2% had higher 3-year DFS, LRRFS and DMFS of 100%, 100% and 100%, respectively (p < 0.05).
Conclusion: Results suggest that ΔADC% was an independent predictor for long-term outcome and was superior to RECIST guideline for outcome prediction in adNPC. A ΔADC% threshold of ≥ 34.2% may be valuable for selecting patients who respond to treatment for de-escalation of treatment or post-treatment surveillance.
Cancer ImagingONCOLOGY-RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING
CiteScore
7.00
自引率
0.00%
发文量
66
审稿时长
>12 weeks
期刊介绍:
Cancer Imaging is an open access, peer-reviewed journal publishing original articles, reviews and editorials written by expert international radiologists working in oncology.
The journal encompasses CT, MR, PET, ultrasound, radionuclide and multimodal imaging in all kinds of malignant tumours, plus new developments, techniques and innovations. Topics of interest include:
Breast Imaging
Chest
Complications of treatment
Ear, Nose & Throat
Gastrointestinal
Hepatobiliary & Pancreatic
Imaging biomarkers
Interventional
Lymphoma
Measurement of tumour response
Molecular functional imaging
Musculoskeletal
Neuro oncology
Nuclear Medicine
Paediatric.